Jeffrey V. Poulton, EVP, Chief Financial Officer at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 6,655 shares at $186.39 ($1.2M) on 2023-08-04, disclosed to the SEC on 2023-08-07.
Open-market sale of $1.2M ALNY by EVP, Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $184.70 | 658 | $122K | 9.8% |
| 2 | $184.70 | 658 | $122K | 9.8% |
| 3 | $185.54 | 1,593 | $296K | 23.9% |
| 4 | $185.54 | 1,593 | $296K | 23.9% |
| 5 | $186.39 | 944 | $176K | 14.2% |
| 6 | $186.39 | 944 |
| $176K |
| 14.2% |
| 7 | $187.37 | 86 | $16K | 1.3% |
| 8 | $188.40 | 15 | $3K | 0.2% |
| 9 | $189.31 | 164 | $31K | 2.5% |
| Total | $185.74 avg | 6,655 | $1.2M | 100% |
| Filing → |
| ALNY | SELL | 2026-02-17 | $695K | — | Filing → |
| ALNY | SELL | 2026-01-14 | $1.0M | — | Filing → |
| ALNY | SELL | 2025-10-03 | $3.4M | — | Filing → |